|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
KAI1 is a metastasis suppressor gene which is capable of inhibiting the processes of tumor metastasis without affecting tumorigenicity per se.
|
10913345 |
2000 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
KAI1 COOH-terminal interacting tetraspanin (KITENIN), a member of the tetraspanin family, interacts with KAI1, a tumor metastasis suppressor, and enhances metastasis of cancer.
|
15205336 |
2004 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
KAI1/CD82 has been reported to attenuate the process of metastases in a variety of tumors; however, its mechanism of action in invasion has not been fully elucidated.
|
21459729 |
2011 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
KAI1 is a tumor metastasis suppressor gene that is capable of inhibiting the metastatic process in animals.
|
9736732 |
1998 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Analyses of metastases with and without KAI1 transfection in mice were different in liver and lung between controls 1.62 +/- 0.39, 0.45 +/- 0.09, pCMV-KAI 1.01 +/- 0.27, 0.33 +/- 0.09 and KAI1-Lipofectamine 0.99 +/- 0.21, 0.30 +/- 0.09 respectively (P < 0.05).
|
18286698 |
2008 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Correlation of the mRNA levels obtained by Northern blot analysis with clinical parameters of the patients revealed that KAI1 mRNA levels were significantly higher (P < 0.01) in earlier tumor stages (I, II), compared with advanced tumor stages (III, IV) in which lymph node or distant metastases were present.
|
8895737 |
1996 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Downregulation of KAI1 has been found to be clinically associated with metastatic progression in a variety of cancers, whereas overexpression of CD82 specifically suppresses tumor metastasis in various animal models.
|
16862154 |
2006 |
|
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Expression of a splice variant of KAI1, a tumor metastasis suppressor gene, influences tumor invasion and progression.
|
14612520 |
2003 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, KAI1 mRNA expression was similar in primary esophageal and gastric cancer samples with or without metastases.
|
9485031 |
1998 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, tumor suppressor genes such as KAI1 are expressed at reduced levels, thereby enhancing the ability of pancreatic cells to form metastases.
|
12120231 |
2001 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
In both cases, we found that the delivery of either MRP-1/CD9 or KAI1/CD82 cDNA dramatically reduced the metastases to the mediastinal lymph nodes in comparison with those of LacZ gene delivery, without affecting the primary tumor growth at the implanted site.
|
17308116 |
2007 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In contrast, most of the primary HCC cells in samples with metastases showed only faint or moderate KAI1 mRNA expression predominantly in the perinuclear regions.
|
9828210 |
1998 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
In multivariate analysis, high VM, Notch4, DLL4 levels, tumor size, LNM, DM, TNM stage, and low KAI1/CD82 levels were potential to be independent prognostic factors for overall survival time (OST) in NSCLC patients.VM and the expression of Notch4, DLL4, and KAI1/CD82 represent promising markers for tumor metastasis and prognosis, and maybe potential therapeutic targets for NSCLC.
|
30593175 |
2018 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In RA-synovium, CD82 was expressed in RASF close to blood vessels, LL, sites of cartilage invasion and colocalised with distinct integrins involved in tumour metastasis suppression but also in RA-synovium by RASF.
|
29980577 |
2018 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In this review, we focus on the differential expression of KAI1/CD82, a tumor metastasis suppressor gene that can inhibit cancer invasion and cell metastasis during NSCLC.
|
29283339 |
2017 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Increased KAI1 expression significantly correlated with distant metastases (Mann-Whitney, p = 0.0001, mRNA; p = 0.033, protein), cancer-specific survival (Cox regression analysis p = 0.0002, mRNA; 0.0493, protein) and overall patient survival (p = 0.0001, mRNA).
|
12530084 |
2003 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Increased level of KAI1/CD82 also results in the suppression of secondary tumour growth.
|
19224455 |
2009 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Induction of KAI-1 expression in metastatic cancer cells by phorbol esters.
|
10779634 |
2000 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
It is suggested that KAI1 gene expression may be related to the metastases of hepatocellular carcinoma.
|
9894767 |
1998 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Kangai 1 (KAI1) is considered as a suppressor gene of tumor metastasis.
|
31725636 |
2019 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our study suggests an association of decreased KAI1/CD82 expression with tumour progression, development of metastases and disease-specific death.
|
18305955 |
2008 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Recently, we have reported the dynamic role of a beta-catenin-reptin chromatin remodelling complex in regulating a metastasis suppressor gene KAI1 (ref.1), which is capable of inhibiting the progression of tumour metastasis.
|
16699503 |
2006 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Role of tumor metastasis suppressor gene KAI1 in digestive tract carcinomas and cancer cells.
|
12955496 |
2003 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
SIGNIFICANCE STATEMENT: The cell-surface and ER transmembrane protein gp78/AMFR, a receptor for the prometastatic autocrine motility factor (AMF), as well as an E3 ubiquitin-ligase involved in the ER-associated degradation (ERAD) of not only the tumor metastatic suppressor KAI1 but also of hepatic cytochromes P450, is upregulated in various human cancers, enhancing their invasiveness, metastatic potential, and poor prognosis.
|
31492698 |
2019 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Statistical analysis of KAI1 mRNA levels and clinical parameters of the patients revealed that KAI1 mRNA levels were significantly higher in non-metastasized tumors compared with tumors in which lymph node or distant metastases were present.
|
9699525 |
1998 |